Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus

Study Overview
=================
Brief Summary
-----------------
Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) and subacute cutaneous lupus erythematosus (SCLE) is a rare phenomenon seldom reported in literature. The investigators hypothesize that clinic-immunologic assessment and detailed investigation of cutaneous biopsy specimen of PPK and erythema of patients suffering from SLE and SCLE could lead to determine more precisely nosological settings of this injury. Report the different therapeutics with efficacy assessment could be helpful to highlight useful treatment for these patients.

Detailed Description
-----------------
Context: Palmoplantar keratoderma (PPK) associated to livid telangiectatic erythema during systemic lupus erythematosus (SLE) is a rare phenomenon seldom reported in literature. To our knowledge no case has been described in subacute cutaneous lupus erythematosus (SCLE) so far. Pathogeny and etiologic origin are not clear: it could be no-specific cutaneous manifestation of SLE, verrucous chilblain lupus, lichen planus, discoid lupus erythematosus lesions, overlap syndrome or coexistence of both diseases. Objective: Determine clinical immunological and histopathological features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE Describe the different therapeutics used and efficacy assessment Methods: Multicentric retrospective descriptive study reporting 14 patients with SLE or SCLE suffering from an acral livid erythematosus keratoderma, with clinical data regarding lupus erythematosus and acral keratoderma, immunological blood samples findings and histopathological results of keratoderma and livid erythema biopsies with direct immunofluorescence if performed. The treatments set down in order to heal are noted followed by efficacy assessment: total failure, partial remission, complete remission.

Official Title
-----------------
Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus : to a Form of Lichen Planus-like Lupus Erythematosus ?

Conditions
-----------------
Systemic Lupus Erythematosus, Lichen Planus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: > 18 years old suffering from SLE or SCLE according to 2019 ACR/EULAR criteria With palmar and or plantar keratoderma with livid telangiectatic erythema Exclusion criteria: < 18 years old suffering from lupus lesions without SLE or SCLE criteria without palmar and or plantar keratoderma with livid telangiectatic erythema

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine clinic immunologic features | Determine clinic immunologic features of patients with PPK and livid telangiectatic erythema-associated suffering from SLE and SCLE. | 1 day | 
| Determine clinic histopathologic features | Epidemiologic clinic immunologic histopathologic data | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Different therapeutics used | Describe the different therapeutics used. Report of the drug therapy used to heal acral keratoderma for each patient | 1 day | 
| Different therapeutics efficacy assessment | Efficacy assessment of the treatments: total failure, partial remission, complete remission | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Palmoplantar keratoderma with livid telangiectatic erythema, Systemic lupus, Subacute lupus erythematosus